Funding agencies: This study was supported by Eisai Inc.
Disclosure: SRS has received research grant support from Amylin Pharmaceuticals, Arena, Eli Lilly, Eisai Inc., Takeda, Isis Pharmaceuticals, Pfizer, and NuSI. He has served as a consultant/advisor to Amylin, Arena, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eisai Inc., Elcelyx, Eli Lilly, Five Prime Therapeutics, GSK, NGM Biopharmaceuticals, Novo Nordisk, Orexigen, Piramal Life Sciences, Takeda, and Zafgen. He is an equity stakeholder in Jenrin Discovery and Zafgen. WTG has served on advisory boards for Eisai Inc., Novo Nordisk, Daiichi-Sankyo, Liposcience, VIVUS, Takeda, Janssen, Boehringer Ingelheim, Alexion, and AstraZeneca and has conducted research with award to the academic institution for Eisai Inc., Merck, Sanofi, AstraZeneca, Weight Watchers, Pfizer, Lexicon, Elcelyx, and Novo Nordisk. FLG has served on advisory boards for BAROnova, Eisai Inc., Curves, Novo Nordisk, Microbiome Therapeutics, Orexigen, Pamlab, PlenSat, and Zafgen. He has consulted for Basic Research, General Nutrition Corporation, Neothetics, Takeda, and Tech Enterprises. He received honorarium for advising Eisai Inc. on study design on the protocol for the 402 study, and his institution, Pennington Biomedical Research Center, received a grant for the study. He filed a patent for Greenway F. Synergy of caffeine with albuterol to increase lean tissue and reduce body fat, US provisional application serial number 61/896,992, filed on October 29, 2013. KF has received research grants through his employer from Eisai Inc., EnteroMedics, Novo Nordisk, Orexigen Therapeutics, and Shire; he has consulted for Ambra, Eisai Inc., EnteroMedics, Gelesis, KVK-Tech, Novo Nordisk, Takeda, and Orexigen; and he is on the speaker bureaus of Abbott, Shire, Takeda, and Novo Nordisk. LJA has served on advisory boards and consulted for Jamieson Labs, Pfizer, Novo Nordisk A/S, Eisai Inc., VIVUS, GI Dynamics, United Health Ventures, and Gelesis; is a shareholder in Zafgen, Gelesis, MYOS Corp., and Jamieson Labs; is on the board of directors for MYOS Corp. and Jamieson Labs; and has received research funding from Aspire Bariatrics and Eisai Inc. EVN and SZ are employees of Eisai Inc. The other authors declared no conflict of interest.
Author contributions: FLG: study design, acquisition of data, manuscript development, interpretation of data; critical revision for important intellectual content; and final approval of the manuscript. CJR wrote the manuscript. All other authors reviewed the manuscript.